Trial Profile
A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Brachyury peptide vaccine (Primary)
- Indications Chordoma
- Focus Therapeutic Use
- Acronyms QUILT-3.011
- Sponsors ImmunityBio
- 31 May 2020 Status changed from active, no longer recruiting to discontinued.
- 31 May 2020 Interim results (n=24) presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 22 Oct 2019 Planned End Date changed from 1 Mar 2020 to 31 Mar 2020.